keyword
MENU ▼
Read by QxMD icon Read
search

Anthracycline

keyword
https://www.readbyqxmd.com/read/28936442/cardiotoxicity-of-cancer-chemotherapy-identification-prevention-and-treatment
#1
REVIEW
Diwakar Jain, Tauseef Ahmad, Mitchel Cairo, Wilbert Aronow
Cardiotoxicity is an important complication of several cancer therapeutic agents. Several well established and newer anticancer therapies such as anthracyclines, trastuzumab and other HER2 receptor blockers, antimetabolites, alkylating agents, tyrosine kinase inhibitors (TKIs), angiogenesis inhibitors, and checkpoint inhibitors are associated with significant cardiotoxicity. Cardiovascular imaging employing radionuclide imaging, echocardiography and magnetic resonance imaging are helpful in early detection and prevention of overt heart failure secondary to cardiotoxicity of cancer therapy...
September 2017: Annals of Translational Medicine
https://www.readbyqxmd.com/read/28934410/approach-to-cardio-oncologic-patients-with-special-focus-on-patients-with-cardiac-implantable-electronic-devices-planned-for-radiotherapy-results-of-the-european-heart-rhythm-association-survey
#2
Radoslaw Lenarczyk, Tatjana S Potpara, Kristina H Haugaa, Jean-Claude Deharo, Antonio Hernandez-Madrid, Maria Del Carmen Exposito Pineda, Marek Kiliszek, Nikolaos Dagres
The aim of this European Heart Rhythm Association (EHRA) survey was to evaluate clinical practice regarding cardio-oncologic patients, with special focus on patients with cardiac implantable electronic devices (CIEDs) planned for anticancer radiotherapy (RT), among members of the EHRA electrophysiology research network. Of the 36 responding centres, 89% managed patients who were diagnosed or treated oncologically, and this diagnosis affected 1-5% of cardiovascular patients in majority of centres (57%). The main side effects of anticancer therapy in patients treated by cardiologists were thromboembolic complications and left ventricular dysfunction (both reported as 'frequent' by 43% of the centres)...
September 1, 2017: Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology
https://www.readbyqxmd.com/read/28933276/cyclophosphamide-and-or-anthracyclines-induced-epiphora-in-breast-cancer-patients-a-rare-side-effect
#3
Ruchika Kalra, Bhavesh Chavada, Nishant R Madhani, Bhargav Purohit, C B Tripathi
Two female breast cancer patients developed epiphora after administration of Cyclophosphamide and/or anthracyclines based 2-day chemotherapy regimen. The ophthalmologist was consulted and no apparent cause was found. Both patients was managed by ciprofloxacin eye drops. Chemotherapy-induced ocular complications are not uncommon, but under-reported. Although epiphora is a mild reaction if severe can interfere with daily activities. Patients receiving anticancer drugs should have a thorough ocular evaluation, in order to prevent, early diagnose and efficiently treat established ocular complications of the chemotherapy treatment...
September 19, 2017: Current Drug Safety
https://www.readbyqxmd.com/read/28931213/a-review-on-the-efficacy-and-toxicity-of-different-doxorubicin-nanoparticles-for-targeted-therapy-in-metastatic-breast-cancer
#4
REVIEW
Ayman Shafei, Wesam El-Bakly, Ahmed Sobhy, Omar Wagdy, Ahmed Reda, Omar Aboelenin, Amr Marzouk, Khalil El Habak, Randa Mostafa, Mahmoud A Ali, Mahmoud Ellithy
In metastatic breast cancer (MBC), the conventional doxorubicin (DOX) has various problems due to lack of selectivity with subsequent therapeutic failure and adverse effects. DOX- induced cardiotoxicity is a major problem that necessitates the presence of new forms to decrease the risk of associated morbidity. Nanoparticles (NPs) are considered an important approach to selectively increase drug accumulation inside tumor cells and thus decreasing the associated side effects. Tumor cells develop resistance to chemotherapeutic agents through multiple mechanisms, one of which is over expression of efflux transporters...
September 16, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28929593/efficacy-of-anthracycline-taxane-based-neo-adjuvant-chemotherapy-on-triple-negative-breast-cancer-in-brca1-brca2-mutation-carriers
#5
Lucie Bignon, Jean-Pierre Fricker, Catherine Nogues, Emmanuelle Mouret-Fourme, Dominique Stoppa-Lyonnet, Olivier Caron, Alain Lortholary, Laurence Faivre, Christine Lasset, Veronique Mari, Paul Gesta, Laurence Gladieff, Akila Hamimi, Thierry Petit, Michel Velten
This study aims to estimate the pathologic complete response (pCR) rate after neo-adjuvant chemotherapy and to compare disease-free survival (DFS) and overall survival (OS) between pCR and non-pCR groups of patients with triple-negative breast cancer (TNBC) and deleterious BRCA1 or BRCA2 mutation. We carried out a retrospective analysis of 53 patients including 46 BRCA1, 6 BRCA2, and 1 combined BRCA1 and BRCA2 mutation. All patients had been diagnosed with triple-negative breast cancer (TNBC) between 1997 and 2014...
September 19, 2017: Breast Journal
https://www.readbyqxmd.com/read/28928469/activation-of-mir-34a-5p-sirt1-p66shc-pathway-contributes-to-doxorubicin-induced-cardiotoxicity
#6
Jie-Ning Zhu, Yong-Heng Fu, Zhi-Qin Hu, Wen-Yu Li, Chun-Mei Tang, Hong-Wen Fei, Hui Yang, Qiu-Xiong Lin, De-Ming Gou, Shu-Lin Wu, Zhi-Xin Shan
The molecular mechanisms underlying anthracyclines-induced cardiotoxicity have not been well elucidated. MiRNAs were revealed dysregulated in the myocardium and plasma of rats received Dox treatment. MicroRNA-34a-5p (miR-34a-5p) was verified increased in the myocardium and plasma of Dox-treated rats, but was reversed in rats received Dox plus DEX treatments. Human miR-34a-5p was also observed increased in the plasma of patients with diffuse large B-cell lymphoma after 9- and 16-week epirubicin therapy. Up-regulation of miR-34a-5p was observed in Dox-induced rat cardiomyocyte H9c2 cells...
September 19, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28922087/preexisting-cardiovascular-risk-and-subsequent-heart-failure-among-non-hodgkin-lymphoma-survivors
#7
Talya Salz, Emily C Zabor, Peter de Nully Brown, Susanne Oksberg Dalton, Nirupa J Raghunathan, Matthew J Matasar, Richard Steingart, Andrew J Vickers, Peter Svenssen Munksgaard, Kevin C Oeffinger, Christoffer Johansen
Purpose The use of anthracycline chemotherapy is associated with heart failure (HF) among survivors of non-Hodgkin lymphoma (NHL). We aimed to understand the contribution of preexisting cardiovascular risk factors to HF risk among NHL survivors. Methods Using Danish registries, we identified adults diagnosed with aggressive NHL from 2000 to 2010 and sex- and age-matched general-population controls. We assessed HF from 9 months after diagnosis through 2012. We used Cox regression analysis to assess differences in risk for HF between survivors and general population controls...
September 18, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28921303/registry-study-to-assess-hair-loss-prevention-with-the-penguin-cold-cap-in-breast-cancer-patients-receiving-chemotherapy
#8
Brooke A Rice, Elizabeth S Ver Hoeve, Amy N DeLuca, Laura J Esserman, Hope S Rugo, Michelle E Melisko
PURPOSE: Chemotherapy-induced alopecia is a distressing side effect of cancer treatment. The aim of this registry study was to assess efficacy and tolerability of scalp hypothermia using Penguin Cold Caps (Penguin) in breast cancer patients. METHODS: Hair loss was assessed by patients using a 100-point Visual Analog Scale (VAS) and by physicians using the 5-point Dean Scale at baseline, every 3-4 weeks during chemotherapy, and at least 1 month after completion of chemotherapy...
September 18, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28916620/the-anthracycline-metabolite-doxorubicinol-abolishes-ryr2-sensitivity-to-physiological-changes-in-luminal-ca-2-through-an-interaction-with-calsequestrin
#9
Amy Hanna, Alexander Lam, Chris Thekkedam, Hermia Willemse, Angela Fay Dulhunty, Nicole Beard
The chemotherapeutic anthracycline metabolite doxorubicinol (doxOL) has been shown to interact with and disrupt the function of the cardiac ryanodine receptor Ca2+ release channel (RyR2) in the sarcoplasmic reticulum (SR) membrane and the SR Ca2+ binding protein calsequestrin2 (CSQ2). Normal increases in RyR2 activity in response to increasing diastolic SR [Ca2+] are influenced by CSQ2 and are disrupted in arrhythmic conditions. Therefore we explored the action of doxOL on RyR2's response to changes in luminal [Ca2+] seen during diastole...
September 15, 2017: Molecular Pharmacology
https://www.readbyqxmd.com/read/28913729/exome-array-analysis-identifies-etfb-as-a-novel-susceptibility-gene-for-anthracycline-induced-cardiotoxicity-in-cancer-patients
#10
Sara Ruiz-Pinto, Guillermo Pita, Miguel Martín, Teresa Alonso-Gordoa, Daniel R Barnes, María R Alonso, Belén Herraez, Purificación García-Miguel, Javier Alonso, Antonio Pérez-Martínez, Antonio J Cartón, Federico Gutiérrez-Larraya, José A García-Sáenz, Javier Benítez, Douglas F Easton, Ana Patiño-García, Anna González-Neira
PURPOSE: Anthracyclines are widely used chemotherapeutic drugs that can cause progressive and irreversible cardiac damage and fatal heart failure. Several genetic variants associated with anthracycline-induced cardiotoxicity (AIC) have been identified, but they explain only a small proportion of the interindividual differences in AIC susceptibility. METHODS: In this study, we evaluated the association of low-frequency variants with risk of chronic AIC using the Illumina HumanExome BeadChip array in a discovery cohort of 61 anthracycline-treated breast cancer patients with replication in a second independent cohort of 83 anthracycline-treated pediatric cancer patients, using gene-based tests (SKAT-O)...
September 14, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28911074/beyond-first-line-non-anthracycline-based-chemotherapy-for-extranodal-nk-t-cell-lymphoma-clinical-outcome-and-current-perspectives-on-salvage-therapy-for-patients-after-first-relapse-and-progression-of-disease
#11
S H Lim, J Y Hong, S T Lim, H Hong, J Arnoud, W Zhao, D H Yoon, T Tang, J Cho, S Park, Y H Ko, S J Kim, C Suh, T Lin, W S Kim
Background: Current standard treatment, including non-anthracycline-based chemotherapy and optimal combining of radiotherapy, has dramatically improved outcomes of patients with extranodal natural killer/T-cell lymphoma (ENKTL) during the last decade. This study was conducted to investigate the clinical outcome of ENKTL patients with relapsed or progressive disease after initial current standard therapy. Patients and methods: We retrospectively reviewed patients diagnosed with ENKTL at six centers in four countries (China, France, Singapore, and South Korea) from 1997 to 2015 and analyzed 179 patients who had relapsed or progressed after initial current standard therapy...
September 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28910957/-effects-of-cell-cycle-regulatory-genes-on-breast-cancer-neo-adjuvant-chemotherapy-by-m-fish
#12
C Y Li, W Su, S Zhang, Y H Hu, J J Liu, J Zhang
Objective: The dysregulation of cell cycle could influence cell proliferation, differentiation and response to medicine. The purpose of this study is to explore the correlation between cell cycle regulatory genes and breast cancer neo-adjuvant chemotherapy (NAC) in patients with local advanced breast cancer, and thus to find some predictors of NAC to provide guidance for clinical treatment. Methods: Ninety five cases of local advanced breast cancer were collected, which were treated with NAC of TAC (Taxanes/Anthracycline/Cyclophosphamide) regimen...
September 12, 2017: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/28910431/hla-mismatched-microtransplant-in-older-patients-newly-diagnosed-with-acute-myeloid-leukemia-results-from-the-microtransplantation-interest-group
#13
Mei Guo, Nelson J Chao, Jian-Yong Li, David A Rizzieri, Qi-Yun Sun, Ann Mohrbacher, Elizabeth F Krakow, Wan-Jun Sun, Xu-Liang Shen, Xin-Rong Zhan, De-Pei Wu, Li Liu, Juan Wang, Min Zhou, Lin-Hua Yang, Yang-Yi Bao, Zheng Dong, Bo Cai, Kai-Xun Hu, Chang-Lin Yu, Jian-Hui Qiao, Hong-Li Zuo, Ya-Jing Huang, Anthony D Sung, Jun-Xiao Qiao, Zhi-Qing Liu, Tie-Qiang Liu, Bo Yao, Hong-Xia Zhao, Si-Xuan Qian, Wei-Wei Liu, Rafael Forés, Rafael F Duarte, Hui-Sheng Ai
Importance: The outcome of older patients with acute myeloid leukemia (AML) remains unsatisfactory. Recent studies have shown that HLA-mismatched microtransplant could improve outcomes in such patients. Objective: To evaluate outcomes in different age groups among older patients with newly diagnosed AML who receive HLA-mismatched microtransplant. Design, Setting, and Participants: This multicenter clinical study included 185 patients with de novo AML at 12 centers in China, the United States, and Spain in the Microtransplantation Interest Group...
September 14, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28905250/tumour-infiltrating-lymphocytes-tils-related-genomic-signature-predicts-chemotherapy-response-in-breast-cancer
#14
Mariko Kochi, Takayuki Iwamoto, Naoki Niikura, Giampaolo Bianchini, Shinobu Masuda, Taeko Mizoo, Tomohiro Nogami, Tadahiko Shien, Takayuki Motoki, Naruto Taira, Yutaka Tokuda, Hiroyoshi Doihara, Junji Matsuoka, Toshiyoshi Fujiwara
PURPOSE: The present study evaluated whether morphological-measured stromal and intra-tumour tumour-infiltrating lymphocytes (TILs) levels were associated with gene expression profiles, and whether TILs-associated genomic signature (GS) could be used to predict clinical outcomes and response to therapies in several breast cancer subtypes. METHODS: We retrospectively evaluated haematoxylin eosin (HE)-TILs levels and gene expression profiling data from 40 patients with primary breast cancer and extracted the 22 overexpressed genes in cases with high TILs scores as the TILs-GS...
September 13, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28901798/multifunctional-micelle-delivery-system-for-overcoming-multidrug-resistance-of-doxorubicin
#15
Li Qin, Lei Wu, Shanshan Jiang, Dandan Yang, Huiyang He, Fang Zhang, Peng Zhang
Doxorubicin, as an anthracycline, plays an important role in chemotherapy. But multidrug resistance tremendously retards the anticancer effect of doxorubicin and results in the failure of chemotherapy. Multifunctional micelles emerge as a valid strategy to load doxorubicin by physical encapsulation or chemical binding to be delivered to cancer cells against multidrug resistance. In this review, mechanism of multidrug resistance of doxorubicin is simply described. Multifunctional co-delivery micelles of doxorubicin and main multidrug resistance modulators have been summarized in detail...
September 13, 2017: Journal of Drug Targeting
https://www.readbyqxmd.com/read/28900472/predictive-and-prognostic-impact-of-tumour-infiltrating-lymphocytes-in-triple-negative-breast-cancer-treated-with-neoadjuvant-chemotherapy
#16
Carmen Herrero-Vicent, Angel Guerrero, Joaquin Gavilá, Francisco Gozalbo, Abraham Hernández, Sergio Sandiego, Maria Asunción Algarra, Ana Calatrava, Vicente Guillem-Porta, Amparo Ruiz-Simón
INTRODUCTION: In locally and locally advanced triple-negative breast cancer (TNBC), neoadjuvant chemotherapy (NAC) only induces a pCR in 30-35% of patients. Clinical and pathological factors are not enough to distinguish the patients who have no chance of a pCR or not. The tumour microenvironment is critical for cancer and tumour-infiltrating lymphocytes (TIL). Moreover, the NAC scenario is the perfect setting to study possible changes in TIL levels. MATERIAL AND METHODS: Using our prospective maintained breast cancer (BC) database, we identified 164 TNBC patients treated with NAC between 1998 and 2015 with enough samples of diagnostic biopsy and after surgery...
2017: Ecancermedicalscience
https://www.readbyqxmd.com/read/28888915/a-case-report-of-locally-advanced-triple-negative-breast-cancer-showing-pathological-complete-response-to-weekly-paclitaxel-with-bevacizumab-treatment-following-disease-progression-during-anthracycline-based-neoadjuvant-chemotherapy
#17
Hideo Shigematsu, Shinji Ozaki, Daisuke Yasui, Taizo Hirata
INTRODUCTION: Neoadjuvant chemotherapy (NAC) is the standard of care for locally advanced triple negative breast cancer, however, approximately 5% of cases show disease progression during NAC. Although downstaging is essential to create an opportunity for curative surgery and to improve the local control outcome in such a case, no additional line of chemotherapy has been established. CASE PRESENTATION: A 60-year-old woman was referred to our hospital for an axillary mass presenting three weeks ago and was diagnosed as having right locally advanced (T2N2M0, stage IIIA) triple negative breast cancer...
September 1, 2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/28887671/histamine-2-receptor-antagonism-elicits-protection-against-doxorubicin-induced-cardiotoxicity-in-rodent-model
#18
Sundar Kumar Kondru, Ajay Godwin Potnuri, Lingesh Allakonda, Prasad Konduri
Doxorubicin (DOX), an anthracycline-based antibiotic, is regularly used in the management of carcinomas, and haematological malignancies have been downplayed in chemotherapy because of its ability to induce dilated cardiomyopathy (DCM). Dexrazoxane is approved to combat the cardiotoxicity, but limited by its adverse effects. Redox imbalance and reactive oxygen species generation plays major role in DOX-induced cardiotoxicity. Histamine, known to mediate various cardiovascular effects, but nevertheless the role of histamine or its receptors in DOX-induced DCM is remained obscure...
September 8, 2017: Molecular and Cellular Biochemistry
https://www.readbyqxmd.com/read/28884410/an-7-a-butyric-acid-prodrug-sensitizes-cutaneous-t-cell-lymphoma-cell-lines-to-doxorubicin-via-inhibition-of-dna-double-strand-breaks-repair
#19
Lilach Moyal, Neta Goldfeiz, Batia Gorovitz, Ada Rephaeli, Efrat Tal, Nataly Tarasenko, Abraham Nudelman, Yael Ziv, Emmilia Hodak
We previously found that the novel histone deacetylase inhibitor (HDACI) butyroyloxymethyl diethylphosphate (AN-7) had greater selectivity against cutaneous T-cell lymphoma (CTCL) than SAHA. AN-7 synergizes with doxorubicin (Dox), an anthracycline antibiotic that induces DNA breaks. This study aimed to elucidate the mechanism underlying the effect of AN-7 on Dox-induced double-strand DNA breaks (DSBs) in CTCL, MyLa and Hut78 cell lines. The following markers/assays were employed: comet assay; western blot of γH2AX and p-KAP1; immunofluorescence of γH2AX nuclear foci; Western blot of repair protein; quantification of DSBs-repair through homologous recombination...
September 8, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/28877720/reduced-ovarian-reserve-in-young-early-breast-cancer-patients-preliminary-data-from-a-prospective-cohort-trial
#20
Antonia Wenners, Jana Grambach, Juliane Koss, Nicolai Maass, Walter Jonat, Andreas Schmutzler, Christoph Mundhenke
BACKGROUND: The numerous side effects of chemotherapy in patients with breast cancer are well known. However, the precise effects of chemotherapy on ovarian function in premenopausal women are poorly investigated. The patients are at risk of developing sexual hormone deficiency and impaired fertility. This prospective cohort study addresses predictive parameters of ovarian reserve after chemotherapy. METHODS: Fifty-one premenopausal women (28-46 years) with primary breast cancer were included in the trial...
September 6, 2017: BMC Cancer
keyword
keyword
12198
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"